Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trialEugenio Mercuri, Katie Groves, Riccardo Masson et al.|The Lancet Neurology|2021Cited by 260
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersenValeria Sansone, Giorgia Coratti, Maria Carmela Pera et al.|European Journal of Neurology|2020Cited by 19